Surgical resection of malignant gastric lesions with no residual lymph nodes in the pathology report also has a chance of metastasis, requiring patients to undergo regular postoperative review to monitor the progress of lesion development. For the treatment of patients with malignant lesions of the stomach, surgical treatment is the mainstay. After gastrectomy, pathological examination of the resected lesions and lymph node tissues is required to clarify the specific lesion typing and metastasis of the patient. Due to the invasive nature of malignant lesions, cancer cells or other malignant lesions can metastasize to local and distant organs through blood pathway, lymphatic pathway, local infiltration or implantation metastasis, and these metastatic processes cannot be recognized by the naked eye. Although the postoperative pathology report shows no residual lymph nodes, patients may have some lymph nodes that cannot be seen with the naked eye or have not been removed by surgery have already metastasized, so there is also a chance of metastasis after surgery. In order to reduce the chance of recurrence of gastric malignant lesions after surgery, radiotherapy and chemotherapy (e.g., vincristine, 5-FU, etc.) will also be routinely administered. In addition to regular treatment, patients must pay attention to regular review after surgery. Through the patient’s basic condition as well as ultrasound, CT and other imaging examinations, the patient’s condition recovery will be analyzed. If any recurrence or metastasis is found, early treatment will be carried out accordingly.